Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo
A legfontosabb adatok
- Ki végzi
- The Children's Hospital of Zhejiang University School of Medicine
- Hol
- Hangzhou (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 3. fázis
- Résztvevők
- 20 fő, tervezett
- Kezdés
- 2026. jún. 1.
- Várható befejezés
- 2028. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Ruxolitinib 1.5% Cream BID
- A regiszteradat frissítve
- 2026. május 19.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for children aged 2 to 11 years with non-segmental vitiligo. They will put Ruxolitinib Phosphate Cream on their white skin patches for 24 weeks.
- Életkor
- 2 to 11 years
- Nem
- All sexes
- A betegség stádiuma
- Non-segmental vitiligo. The affected skin is at least 0.1% of the body surface (BSA), with a T-VASI score of at least 0.1. The total white area is not more than 10% of the body surface.
- Korábbi kezelés
- Children cannot join if they have ever used, or now use, any treatment for loss of skin colour. Children cannot join if any JAK inhibitor treatment, by mouth or on the skin, did not work for vitiligo or another inflammatory condition.
A részvétel fő kizáró okai
- Other forms of vitiligo, such as segmental vitiligo
- Other skin conditions that cause pale or white patches, such as pityriasis alba, leprosy or tinea versicolor
- Known allergy to the study drug or its ingredients
- Taking part in another clinical trial at the same time
- Any other reason the study doctor judges makes the child unable to take part
A regiszter feltételei, szó szerint
Mind a 10 feltétel megnézéseKevesebb
Ki vehet részt
- Children aged 2 to 11 years, regardless of sex
- Clinical diagnosis of non-segmental vitiligo, with affected Body Surface Area (BSA) ≥0.1%, T-VASI score ≥0.1, and total depigmented area not exceeding 10% BSA
- Legal guardian voluntarily provides signed informed consent and agrees to scheduled follow-ups
Ki nem vehet részt
- Prior or current use of any treatment for depigmentation
- Concurrent participation in another clinical trial
- Presence of other hypopigmentary or depigmentary disorders that could interfere with efficacy assessment (e.g., pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macular hypomelanosis, nevus depigmentosus, and tinea versicolor)
- History of failure with any systemic or topical JAK inhibitor therapy for vitiligo or any other inflammatory condition
- Known hypersensitivity to the study drug or its excipients
- Diagnosis of other forms of vitiligo (e.g., segmental vitiligo)
- Considered by the investigator to be unsuitable for the study for any other reason
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 2 és 11 év között vagy?
Helyszínek itt: Kína
- Children's Hospital, Zhejiang University School of MedicineHangzhou, KínaContact: Yunqing RenToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to evaluate the efficacy and safety of Ruxolitinib Phosphate Cream in treating non-segmental vitiligo in children aged 2 to 11 years under real-world conditions. The main question[s] it aims to answer are:
A teljes eredeti leírásKevesebb
Primary Efficacy: What is the improvement rate (e.g., proportion of participants achieving F-VASI75) after 24 weeks of treatment with Ruxolitinib Phosphate Cream in this population? Safety Profile: What is the safety profile of the treatment over 24 weeks, specifically regarding the incidence of Application Site Acne, Application Site Pruritus, and other adverse events?
Participants will:
Apply Ruxolitinib Phosphate Cream topically to vitiligo lesions as prescribed by the investigator.
Attend scheduled clinic visits at Weeks 4, 8, 12, and 24 for efficacy and safety assessments.
Undergo standardized clinical photography and severity scoring of their vitiligo lesions at each visit.
Report any adverse events or skin reactions experienced during the study period to the research team.
A vizsgálat csoportja
- Ruxolitinib treatmentA vizsgált kezelés
In this single-arm clinical trial, all eligible subjects will receive the same investigational intervention. The study drug is Ruxolitinib Phosphate Cream, 1.5% (w/w), supplied in 100 g tubes. The dosing regimen consists of applying a thin layer of the cream to all vitiligo lesions twice daily, with approximately 12 hours between applications. Throughout the treatment period, the total application area must not exceed 10% of the Body Surface Area, and the maximum usage is limited to two tubes (totaling 200 g) per month. The entire investigational intervention will last for 24 weeks, unless a subject meets early discontinuation criteria beforehand. It must be emphasized that this drug is for cutaneous use only and is strictly prohibited for application to mucous membranes (e.g., inside the mouth, vagina) or in or around the eyes.
Kezelés: Ruxolitinib 1.5% Cream BID
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Efficacy and Safety of Ruxolitinib Cream in Children Aged 2-11 Years With Non-segmental Vitiligo: A Single-Center, Real-World Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07595939: ki vehet részt
- A regiszteradat frissítve
- 2026. május 19.